ALX Oncology Inc.
ALXO · Nasdaq · United States
Share price · ALXO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ALXO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026-13.6%
- 2 Nov 2026+12.3%
Nothing announced by ALXO that day or the session before.
- 16 Oct 2026+6.0%
- 15 Oct 2026+11.8%
- 14 Oct 2026-8.7%
Nothing announced by ALXO that day or the session before.
- 13 Oct 2026-22.3%
Nothing announced by ALXO that day or the session before.
- 24 Sep 2026-7.8%
Nothing announced by ALXO that day or the session before.
- 6 Aug 2026+9.9%
- 9 Jul 2026-11.6%
Nothing announced by ALXO that day or the session before.
- 26 Jun 2026+14.0%
Share of unusual movement by asset
For each asset, the share of ALXO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | CD47Protein / enzyme therapeutic | Multiple MyelomaBreast Cancer HER2-Positive Breast Cancer | |
| Phase 1 | EGFRAntibody–drug conjugate | Non-Small Cell Lung Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $13M | $23M+ $116M short-term inv. | $18M-$16M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $14M | $32M+ $108M short-term inv. | $18M-$19M operating cash flow | report ↗ |
| 2025-Q3 | — | $17M | $24M+ $37M short-term inv. | $22M-$17M operating cash flow | report ↗ |
| 2025-Q2 | — | $18M | $19M+ $60M short-term inv. | $26M-$23M operating cash flow | report ↗ |
| 2025-Q1 | — | $24M | $21M+ $77M short-term inv. | $31M-$25M operating cash flow | report ↗ |
| 2024-Q3 | — | $26M | $16M+ $132M short-term inv. | $31M-$25M operating cash flow | report ↗ |
| 2024-Q2 | — | $35M | $16M+ $141M short-term inv. | $39M-$27M operating cash flow | report ↗ |
| 2024-Q1 | — | $32M | $14M+ $143M short-term inv. | $36M-$38M operating cash flow | report ↗ |
| 2023-Q3 | — | $46M | $20M+ $170M short-term inv. | $51M-$31M operating cash flow | report ↗ |
| 2023-Q2 | — | $29M | $38M+ $175M short-term inv. | $34M-$32M operating cash flow | report ↗ |
| 2023-Q1 | — | $25M | $63M+ $165M short-term inv. | $30M-$28M operating cash flow | report ↗ |
| 2022-Q3 | — | $29M | $49M+ $236M short-term inv. | $35M-$31M operating cash flow | report ↗ |
| 2022-Q2 | — | $27M | $66M+ $247M short-term inv. | $33M-$17M operating cash flow | report ↗ |
| 2022-Q1 | — | $17M | $159M+ $158M short-term inv. | $25M-$21M operating cash flow | report ↗ |
| 2021-Q3 | — | $18M | $385M | $25M-$25M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $77M | $16M+ $28M short-term inv. | $25M-$84M operating cash flow | report ↗ |
ALX Oncology reported full-year 2025 financials with revenue not disclosed. R&D expenses were $77.0M, down 33.8% YoY from $116.4M. Cash and equivalents stood at $16.44M, while cash, cash equivalents and investments totaled $48.3M as of December 31, 2025. GAAP net loss for the year was $101.7M versus $134.9M in 2024, including a Q4 2025 net loss of $22.8M.
The company guided that existing cash, plus $140.4M in net proceeds from its February 2026 registered offering, should fund operations through 1H 2028. Clinical development for evorpacept and ALX2004 remains on track: ASPEN-09-Breast top-line data are anticipated mid-2027, ALX2004 dose-escalation safety data in 2H 2026, and the full biomarker analysis from the evorpacept-zanidatamab Phase 1b/2 trial was accepted for presentation at ESMO Breast Cancer 2026. Barbara Klencke was also appointed permanent Chief Medical Officer.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $116M | $18M+ $110M short-term inv. | $34M-$122M operating cash flow | report ↗ |
| 2023-FY | — | $142M | $22M+ $160M short-term inv. | $40M-$130M operating cash flow | report ↗ |
| 2022-FY | $0 | $98M | $49M+ $217M short-term inv. | $31M-$89M operating cash flow | report ↗ |
| 2021-FY | $0 | $60M | $364M | $21M-$68M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($5.0M), 7 sales ($43K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-17 | Wong Shelly · SVP, FINANCE AND CAO | Open-market sale | 573 | $1.93 | $1K | Form 4 |
| 2026-08-17 | Lettmann Jason · director, CHIEF EXECUTIVE OFFICER | Open-market sale | 2,230 | $1.93 | $4K | Form 4 |
| 2026-07-01 | Wong Shelly · SVP, FINANCE AND CAO | Open-market sale | 1,404 | $2.04 | $3K | Form 4 |
| 2026-04-16 | Klencke Barbara · Chief Medical Officer | Award / grant (derivative) | 100,000 | — | — | Form 4 |
| 2026-04-16 | Knight Jeff E. · Chief Dev & Operating Officer | Award / grant (derivative) | 800,000 | — | — | Form 4 |
| 2026-03-19 | Pinto Shelly · SVP, FINANCE AND CAO | Open-market sale | 903 | $2.17 | $2K | Form 4 |
| 2026-03-19 | Lettmann Jason · director, CHIEF EXECUTIVE OFFICER | Open-market sale | 12,311 | $2.17 | $27K | Form 4 |
| 2026-03-03 | Klencke Barbara · Chief Medical Officer | Award / grant (derivative) | 700,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 69 reporting institutions held 94.3M shares ($186.7M, 68.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 13,011,849 | $26.1M |
| 2 | TCG Crossover Management, LLC | 13,011,849 | $26.1M |
| 3 | venBio Partners LLC | 12,884,638 | $25.8M |
| 4 | Redmile Group, LLC | 7,964,188 | $16.0M |
| 5 | Blackstone Inc. | 5,826,544 | $11.7M |
| 6 | Driehaus Capital Management LLC | 5,734,620 | $11.5M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 4,179,736 | $8.4M |
| 8 | MARSHALL WACE, LLP | 3,757,216 | $7.5M |
| 9 | Vivo Capital, LLC | 3,184,713 | $6.4M |
| 10 | Almitas Capital LLC | 3,173,834 | $6.4M |
| 11 | 5AM Venture Management, LLC | 3,057,325 | $6.1M |
| 12 | ORBIMED ADVISORS LLC | 2,866,256 | $5.7M |
| 13 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,000,000 | $4.0M |
| 14 | MILLENNIUM MANAGEMENT LLC | 1,988,559 | $4.0M |
| 15 | TWO SIGMA INVESTMENTS, LP | 1,587,833 | $3.2M |